Trevena (NASDAQ:TRVN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Saturday. They currently have a $2.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 14.29% from the company’s current price.
According to Zacks, “Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company’s product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. “
Other equities research analysts have also recently issued reports about the company. Oppenheimer set a $5.00 price objective on Trevena and gave the company a “buy” rating in a research note on Thursday, October 12th. HC Wainwright lowered their price objective on Trevena from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, October 12th. Barclays cut Trevena from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $15.00 to $2.50 in a research note on Monday, October 16th. Finally, Needham & Company LLC lowered their price objective on Trevena from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $8.05.
Trevena (NASDAQ:TRVN) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.06. During the same period in the prior year, the firm earned ($0.57) earnings per share. research analysts predict that Trevena will post -1.23 earnings per share for the current fiscal year.
A number of hedge funds have recently bought and sold shares of TRVN. Nationwide Fund Advisors grew its holdings in Trevena by 92.1% during the 2nd quarter. Nationwide Fund Advisors now owns 49,132 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 23,557 shares in the last quarter. Alliancebernstein L.P. grew its holdings in Trevena by 51.9% during the 2nd quarter. Alliancebernstein L.P. now owns 55,300 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 18,900 shares in the last quarter. Virtu KCG Holdings LLC grew its holdings in Trevena by 144.0% during the 2nd quarter. Virtu KCG Holdings LLC now owns 58,660 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 34,618 shares in the last quarter. Rhumbline Advisers grew its holdings in Trevena by 30.1% during the 2nd quarter. Rhumbline Advisers now owns 64,251 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 14,880 shares in the last quarter. Finally, Bourgeon Capital Management LLC grew its holdings in Trevena by 63.1% during the 3rd quarter. Bourgeon Capital Management LLC now owns 86,500 shares of the biopharmaceutical company’s stock valued at $221,000 after buying an additional 33,469 shares in the last quarter. 56.10% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Trevena (TRVN) Rating Lowered to Hold at Zacks Investment Research” was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/20/trevena-trvn-rating-lowered-to-hold-at-zacks-investment-research.html.
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.